Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited
Search jobs Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited Osaka, Japan, April 1, 2021 --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the asset transfer associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited (“Teijin Pharma”) for JPY 133.0 billion ®, Liovel ® and Zafatek ®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019. While the products included in the asset transfer continue to pl...